DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-10.55%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$353M
AUM Growth
+$353M
(-10%)
Cap. Flow
+$9.89M
Cap. Flow
% of AUM
2.8%
Top 10 Holdings %
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7
Top Buys
| 1 |
Arcus Biosciences
RCUS
|
$2.91M |
| 2 |
Mineralys Therapeutics
MLYS
|
$2.58M |
| 3 |
Stoke Therapeutics
STOK
|
$1.81M |
| 4 |
Inogen
INGN
|
$1.78M |
| 5 |
Denali Therapeutics
DNLI
|
$1.74M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$3.58M |
| 2 |
Axogen
AXGN
|
$3.07M |
| 3 |
AtriCure
ATRC
|
$1.59M |
| 4 |
Alkermes
ALKS
|
$875K |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$816K |
Sector Composition
| 1 | Healthcare | 85.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $32.8M | 9.3% | 404,505 +7,000 | +2% | +$568K |
|
2
Stereotaxis
STXS
$261M
| $24.1M | 6.83% | 13,680,554 | – | – |
|
3
Revolution Medicines
RVMD
$7.1B
| $23.2M | 6.58% | 656,176 +25,000 | +4% | +$884K |
|
4
Merus
MRUS
$4.98B
| $19.4M | 5.51% | 461,804 +10,000 | +2% | +$421K |
|
|
5
AtriCure
ATRC
$1.84B
| $19.1M | 5.42% | 592,273 -49,400 | -8% | -$1.59M |
|
6
Cytokinetics
CYTK
$4.23B
| $16M | 4.54% | 398,100 | – | – |
|
|
BPMC
7
DELISTED
Blueprint Medicines
BPMC
| $13.5M | 3.82% | 152,263 +2,500 | +2% | +$221K |
|
8
iShares Biotechnology ETF
IBB
$5.6B
| $13.1M | 3.72% | 102,500 | – | – |
|
|
9
Axogen
AXGN
$743M
| $12.6M | 3.57% | 680,782 -166,100 | -20% | -$3.07M |
|
|
10
Ascendis Pharma
ASND
$11.8B
| $12.5M | 3.55% | 80,398 -22,957 | -22% | -$3.58M |
|
11
IDEAYA Biosciences
IDYA
$2.15B
| $9.65M | 2.74% | 589,330 +90,503 | +18% | +$1.48M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $9.18M | 2.6% | 273,739 | – | – |
|
13
KalVista Pharmaceuticals
KALV
$678M
| $8.68M | 2.46% | 752,359 -59,319 | -7% | -$685K |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $7.92M | 2.25% | 71,615 | – | – |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.69M | 1.9% | 544,502 +2,500 | +0.5% | +$30.7K |
|
16
Day One Biopharmaceuticals
DAWN
$769M
| $5.8M | 1.64% | 731,363 | – | – |
|
17
Tandem Diabetes Care
TNDM
$845M
| $5.64M | 1.6% | 294,208 +71,000 | +32% | +$1.36M |
|
18
UroGen Pharma
URGN
$900M
| $5.45M | 1.54% | 492,515 | – | – |
|
19
Biohaven
BHVN
$1.63B
| $5.29M | 1.5% | 220,235 | – | – |
|
|
20
Mineralys Therapeutics
MLYS
$1.03B
| $4.91M | 1.39% | 309,200 +162,700 | +111% | +$2.58M |
|
|
21
Arcus Biosciences
RCUS
$1.13B
| $4.91M | 1.39% | 625,126 +370,909 | +146% | +$2.91M |
|
22
DexCom
DXCM
$29.5B
| $4.48M | 1.27% | 65,552 | – | – |
|
|
23
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.19M | 1.19% | 558,255 -108,745 | -16% | -$816K |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $4.03M | 1.14% | 183,140 -4,000 | -2% | -$88K |
|
25
Galapagos
GLPG
$2.07B
| $3.27M | 0.93% | 130,175 | – | – |
|